Newsletters

[Cancer Cell] Using multiplexed single-cell proteomics to analyze 50 tumor microenvironment-associated proteins across treatment-naive triple-negative breast cancer specimens, we discovered that CSCs drive differentiation and expansion of regulatory T cells via extracellular vesicle-mediated paracrine signaling.

[Cell Stem Cell] Researchers revealed four distinct leukemic stem cell types with unique vulnerabilities and propose biomarker-guided treatment strategies that complement genetic profiling to overcome venetoclax resistance.

[Cell Stem Cell] Scientists showed that leukemic stem cells in acute myeloid leukemia exhibit elevated ketogenesis, driven by fatty acid oxidation, to produce β-hydroxybutyrate.

[Nature Communications] Investigators showed that recurrent L122R mutation in the DNA-binding site of the Myogenic Differentiation 1 (MYOD1) transcription factor increases cancer stem cell frequency in aggressive Spindle cell/sclerosing rhabdomyosarcoma.

[Nature Communications] Researchers found that increased matrix stiffness promotes radioresistance in glioblastoma and maintains tumor cell hierarchies.

[Cancer Letters] Scientists established a novel syngeneic glioblastoma stem cell line from PDGFB-driven RCAS/tv-a glioblastomas and subsequently generated a Pten-deficient derivative, WYZ-1.

[Cell Death & Disease] Investigators demonstrated that inhibition of ONECUT2, a core transcription factor, potently drives CSC characteristics and reprograms the TIME to favor macrophage polarization to the M2-type, a tumor-promoting state.

[Oncogene] Scientists demonstrated that S100A8 was highly expressed in glioblastoma (GBM) stem cells and closely associated with shorter overall survival in GBM patients.

[Experimental & Molecular Medicine] Investigators discuss the emerging potential of targeting CSC-supportive metabolic niches through drug repurposing, highlighting context-aware metabolic interventions as a pragmatic strategy to overcome CSC-driven treatment resistance.

[Cancer Letters] The authors provide a comprehensive analysis of the evolving landscape of immunotherapies designed to target colorectal cancer stem-like cells.

[Lyell Immunopharma, Inc.] Lyell Immunopharma, Inc. provided an update on the safety profile of LYL273 in its ongoing US Phase I clinical trial in patients with relapsed or refractory metastatic colorectal cancer, and announced the Phase I trial has been amended to enable seamless expansion into a potential pivotal single-arm Phase II trial pending regulatory alignment.

[Nature] Researchers showed that malignant cell states transcriptionally resemble stages of normal glial–neuronal lineage development or a reactive mesenchymal-like state, mirroring states previously described in isocitrate dehydrogenase (IDH) wild-type glioblastoma.